Related Experiment Videos
Does a sedative dose of chloral hydrate modify the EEG of children with epilepsy?
M Thoresen1, O Henriksen, E Wannag
1National Center for Epilepsy, Sandvika, Norway. marianne.thoresen@ioks.uio.no
Insights
Chloral hydrate (CH) effectively sedates children for EEG, but can alter seizure activity in some cases. Further research is needed to understand CH
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Chloral hydrate (CH) is a common sedative for pediatric electroencephalography (EEG).
- Its effects on EEG patterns, particularly in children with epilepsy, are not well understood.
Purpose of the Study:
- To investigate the impact of chloral hydrate on EEG activity in children with severe epilepsy.
- To determine if CH or its metabolites alter epileptic activity or background EEG patterns.
Main Methods:
- Rectal administration of chloral hydrate (50-77 mg/kg) to 13 children (1.5-13.5 years) with severe epilepsy.
- EEG recordings were obtained before, during, and after CH administration.
- Cardiovascular parameters were monitored throughout the study.
Main Results:
- No significant EEG changes were observed in 9 out of 13 children.
- A reduction in epileptic activity occurred in 3 children within 20-50 minutes post-administration.
- An increase in epileptic activity was noted in one child.
- Cardiovascular parameters remained stable in all participants.
Conclusions:
- Chloral hydrate can be used for sedation during EEG in most children with epilepsy.
- However, alterations in epileptic activity were observed in a subset of patients, potentially affecting EEG interpretation.
- The study highlights the need for careful consideration of CH's potential modulatory effects on seizure activity.
Abstract:
Chloral hydrate (CH) is used to sedate children unable to cooperate during investigations such as EEG requiring the patient to be still. It is not known if CH or its metabolites modify the EEG and our aim was to answer this question. Recordings of the EEG before, during and after rectal administration of CH (50-77 mg/kg) in 13 children aged 1.5-13.5 years with severe epilepsy and additional neurological impairments were made. All children had frequent spike-wave activity before CH. In 9 children CH had no effect on the EEG. In 3 children there was a significant reduction in epileptic activity after 20-50 min and in one a significant increase. Cardiovascular parameters were stable throughout. At sedative doses, CH can generally be used before an EEG recording without loss of information but in 4 out of 13 children there were changes which could alter interpretation.